{"id":574,"date":"2015-06-03T16:42:12","date_gmt":"2015-06-03T11:12:12","guid":{"rendered":"https:\/\/delveinsightblog.wordpress.com\/?p=574"},"modified":"2025-05-05T17:35:53","modified_gmt":"2025-05-05T12:05:53","slug":"outbreak-of-companies-challenging-new-pathways-for-treatment-of-pulmonary-arterial-hypertension","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/outbreak-of-companies-challenging-new-pathways-for-treatment-of-pulmonary-arterial-hypertension","title":{"rendered":"Outbreak of Companies Challenging New Pathways for Treatment of Pulmonary Arterial Hypertension"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a00479d2f5a3\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a00479d2f5a3\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><ul class='ez-toc-list-level-4' ><li class='ez-toc-heading-level-4'><ul class='ez-toc-list-level-4' ><li class='ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/outbreak-of-companies-challenging-new-pathways-for-treatment-of-pulmonary-arterial-hypertension\/#Drugs_with_better_pharmacodymics_and_improved_treatment_algorithm_with_antiproliferative_and_anti-inflammatory_treatments_are_needed\" >Drugs with better pharmacodymics and improved treatment algorithm with antiproliferative and anti-inflammatory treatments are needed!<\/a><\/li><\/ul><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/outbreak-of-companies-challenging-new-pathways-for-treatment-of-pulmonary-arterial-hypertension\/#Research_over_last_five_years\" >Research over last five years<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/outbreak-of-companies-challenging-new-pathways-for-treatment-of-pulmonary-arterial-hypertension\/#Pharmaceutical_Companies_Researching_in_PAH\" >Pharmaceutical Companies Researching in PAH<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/outbreak-of-companies-challenging-new-pathways-for-treatment-of-pulmonary-arterial-hypertension\/#DelveInsight_Expert_Comments\" >DelveInsight Expert Comments<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/outbreak-of-companies-challenging-new-pathways-for-treatment-of-pulmonary-arterial-hypertension\/#Upcoming_Report_Pulmonary_Arterial_Hypertension_%E2%80%93_Competitive_Landscape_Market_Pipeline_Analysis_Forecasted_Market_Size_2015-2020\" >Upcoming Report:Pulmonary Arterial Hypertension &#8211; Competitive Landscape, Market &amp; Pipeline Analysis, Forecasted Market Size 2015-2020<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<p style=\"text-align: justify;\"><img decoding=\"async\" class=\"  wp-image-575 alignright\" src=\"https:\/\/delveinsightblog.files.wordpress.com\/2015\/06\/2.jpg\" alt=\"2\" width=\"216\" height=\"144\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2015\/06\/09022644\/2.jpg 1200w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2015\/06\/09022644\/2-300x200.jpg 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2015\/06\/09022644\/2-768x512.jpg 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2015\/06\/09022644\/2-1024x683.jpg 1024w\" sizes=\"(max-width: 216px) 100vw, 216px\" \/><\/p>\n<blockquote>\n<h4 style=\"text-align: left;\"><span class=\"ez-toc-section\" id=\"Drugs_with_better_pharmacodymics_and_improved_treatment_algorithm_with_antiproliferative_and_anti-inflammatory_treatments_are_needed\"><\/span><span style=\"color: #993366;\">Drugs with better pharmacodymics and improved treatment algorithm with antiproliferative and anti-inflammatory treatments are need<\/span><span style=\"color: #993366;\">ed!<\/span><span class=\"ez-toc-section-end\"><\/span><\/h4>\n<\/blockquote>\n<p style=\"text-align: justify;\">Pulmonary arterial hypertension (PAH) is rare lung disorder affecting pulmonary arteries. It is a fatal disease associated with the vasoconstriction and vascular remodeling that is characterized by progressive increase of pulmonary pressure and resistance leading to right heart failure. In most of the cases this disease is diagnosed in the late stage classified by WHO as Class III and IV. PAH is categorized as group one under pulmonary hypertension. History reports the emergence of this disease back in 1891 with the concept of hemodynamics. In 1973, World Health Organization (WHO) categorized the pressure rise in pulmonary arteries as primary and secondary pulmonary hypertension. Although it is a rare disease but it has estimated prevalence of 15-50 cases per million. Epoprostenol, a prostacyclin analog was the first drug to provide treatment for pulmonary arterial hypertension which was followed by improved therapies in oral forms acting as phosphodiesterase V inhibitors and endothelin receptor antagonists (ERAs). These therapies are designed to stimulate relaxation of pulmonary arteries but are not directly targeting vascular remodeling.<\/p>\n<h2 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Research_over_last_five_years\"><\/span>Research over last five years<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"text-align: justify;\">Recently within past 5 years, there have been major advances in the treatment option for PAH with better understanding of pathophysiology. Newer paradigms have paved way for the future development of novel therapeutics targets. <strong><span style=\"color: #ff6600;\">Endothelial dysfunction<\/span><\/strong> has become a major area of interest as therapeutic target for treatment of PAH. Other targets explored recently include <strong><span style=\"color: #993366;\">Tyrosine Kinase (TK) inhibitors which involve growth factors such as bFGF, PDGF and EGF; Rho-kinases in signaling pathways, Dehydroepiandrosterone, miRNA, Gene therapy and Stem cell therapy<\/span>.<\/strong> Combination therapies of approved drugs are also used in the clinical trials but it remains unknown whether it will prove to be more effective than other drugs. More than 20 drugs have reached in the clinical trials for the treatment of PAH indication.<\/p>\n<h2 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Pharmaceutical_Companies_Researching_in_PAH\"><\/span>Pharmaceutical Companies Researching in PAH<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"text-align: justify;\">Novarts AG, GlaxoSmithKline PLC, Pfizer Inc and Eli Lilly &amp; Co. are few giant bio-pharmaceutical companies whose products are in phase III and acts on novel therapeutic targets. Gilead Biosciences is coming up with the combination therapy in phase III. These all companies are expected to provide huge competition in the market to some of the already marketed drugs such as Tracleer (bosentan) which is set to go off-patent in US and Europe in 2015 and 2017. Other companies to look up to in future include Arena Pharmaceuticals, Inc., Dong-A PharmTech Co., Ltd. and Reata Pharmaceuticals. Celladon Corporation, miRagen Therapeutics, Inc., Silence Therapeutics and Northern Therapeutics, Inc. are other companies which are establishing themselves for the treatment of PAH by targeting gene, stem cell and micro RNA.<\/p>\n<h2 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"DelveInsight_Expert_Comments\"><\/span>DelveInsight Expert Comments<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"text-align: justify;\">The current treatments have shown symptomatic improvements but they do not provide the evidence of long term survival. The future clinical trials for PAH looks complex and challenging as it is an orphan disease deep insight knowledge of molecular biology. Drugs with better pharmacodymics and improved treatment algorithm with antiproliferative and anti-inflammatory treatments are needed that will target the pulmonary disease more specifically.<\/p>\n<p><em>Written by Tarun Jain, Associate Analyst at DelveInsight<\/em><\/p>\n<h3><span class=\"ez-toc-section\" id=\"Upcoming_Report_Pulmonary_Arterial_Hypertension_%E2%80%93_Competitive_Landscape_Market_Pipeline_Analysis_Forecasted_Market_Size_2015-2020\"><\/span>Upcoming Report:<span class=\"il\">Pulmonary Arterial<\/span> Hypertension &#8211; Competitive Landscape, Market &amp; Pipeline Analysis, Forecasted Market Size 2015-2020<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<div id=\":2ic\" class=\"pG\">For more information on this Report, mail us at info@<span class=\"skimlinks-unlinked\">delveinsight.com<\/span><\/div>\n<p><strong><em>Lets share our knowledge, provide your comments in the\u00a0comment section<\/em><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Drugs with better pharmacodymics and improved treatment algorithm with antiproliferative and anti-inflammatory treatments are needed! Pulmonary arterial hypertension (PAH) is rare lung disorder affecting pulmonary arteries. It is a fatal disease associated with the vasoconstriction and vascular remodeling that is characterized by progressive increase of pulmonary pressure and resistance leading to right heart failure. In [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[81,180,204,249,268,269,347,373,17255,448,461,499,580],"industry":[17225],"therapeutic_areas":[17242,17234],"class_list":["post-574","post","type-post","status-publish","format-standard","hentry","category-articles","tag-antiproliferative-and-anti-inflammatory-treatments","tag-competitive-landscape","tag-delveinsight","tag-forecasted-market-size-2015-2020","tag-gilead-biosciences","tag-glaxosmithkline-plc","tag-last-five-years","tag-market-pipeline-analysis","tag-novartis-ag","tag-pah","tag-pfizer-inc-and-eli-lilly-co","tag-pulmonary-arterial-hypertension","tag-tracleer-bosentan","industry-pharmaceutical","therapeutic_areas-cardiovascular-diseases","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Outbreak of Companies Challenging New Pathways for Treatment<\/title>\n<meta name=\"description\" content=\"Pulmonary arterial hypertension is rare lung disorder affecting pulmonary arteries. It is a fatal disease associated with the vasoconstriction...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/outbreak-of-companies-challenging-new-pathways-for-treatment-of-pulmonary-arterial-hypertension\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Outbreak of Companies Challenging New Pathways for Treatment\" \/>\n<meta property=\"og:description\" content=\"Pulmonary arterial hypertension is rare lung disorder affecting pulmonary arteries. It is a fatal disease associated with the vasoconstriction...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/outbreak-of-companies-challenging-new-pathways-for-treatment-of-pulmonary-arterial-hypertension\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2015-06-03T11:12:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-05T12:05:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/delveinsightblog.files.wordpress.com\/2015\/06\/2.jpg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Outbreak of Companies Challenging New Pathways for Treatment","description":"Pulmonary arterial hypertension is rare lung disorder affecting pulmonary arteries. It is a fatal disease associated with the vasoconstriction...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/outbreak-of-companies-challenging-new-pathways-for-treatment-of-pulmonary-arterial-hypertension","og_locale":"en_US","og_type":"article","og_title":"Outbreak of Companies Challenging New Pathways for Treatment","og_description":"Pulmonary arterial hypertension is rare lung disorder affecting pulmonary arteries. It is a fatal disease associated with the vasoconstriction...","og_url":"https:\/\/www.delveinsight.com\/blog\/outbreak-of-companies-challenging-new-pathways-for-treatment-of-pulmonary-arterial-hypertension","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2015-06-03T11:12:12+00:00","article_modified_time":"2025-05-05T12:05:53+00:00","og_image":[{"url":"https:\/\/delveinsightblog.files.wordpress.com\/2015\/06\/2.jpg","type":"","width":"","height":""}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/outbreak-of-companies-challenging-new-pathways-for-treatment-of-pulmonary-arterial-hypertension","url":"https:\/\/www.delveinsight.com\/blog\/outbreak-of-companies-challenging-new-pathways-for-treatment-of-pulmonary-arterial-hypertension","name":"Outbreak of Companies Challenging New Pathways for Treatment","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/outbreak-of-companies-challenging-new-pathways-for-treatment-of-pulmonary-arterial-hypertension#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/outbreak-of-companies-challenging-new-pathways-for-treatment-of-pulmonary-arterial-hypertension#primaryimage"},"thumbnailUrl":"https:\/\/delveinsightblog.files.wordpress.com\/2015\/06\/2.jpg","datePublished":"2015-06-03T11:12:12+00:00","dateModified":"2025-05-05T12:05:53+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Pulmonary arterial hypertension is rare lung disorder affecting pulmonary arteries. It is a fatal disease associated with the vasoconstriction...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/outbreak-of-companies-challenging-new-pathways-for-treatment-of-pulmonary-arterial-hypertension"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/outbreak-of-companies-challenging-new-pathways-for-treatment-of-pulmonary-arterial-hypertension#primaryimage","url":"https:\/\/delveinsightblog.files.wordpress.com\/2015\/06\/2.jpg","contentUrl":"https:\/\/delveinsightblog.files.wordpress.com\/2015\/06\/2.jpg"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":null,"coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">antiproliferative and anti-inflammatory treatments<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Competitive landscape<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Forecasted Market Size 2015-2020<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Gilead Biosciences<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">GlaxoSmithKline PLC<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">last five years<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Market &amp; Pipeline Analysis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Novartis AG<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">PAH<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Pfizer Inc and Eli Lilly &amp; Co<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Pulmonary arterial hypertension<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Tracleer (bosentan)<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">antiproliferative and anti-inflammatory treatments<\/span>","<span class=\"advgb-post-tax-term\">Competitive landscape<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">Forecasted Market Size 2015-2020<\/span>","<span class=\"advgb-post-tax-term\">Gilead Biosciences<\/span>","<span class=\"advgb-post-tax-term\">GlaxoSmithKline PLC<\/span>","<span class=\"advgb-post-tax-term\">last five years<\/span>","<span class=\"advgb-post-tax-term\">Market &amp; Pipeline Analysis<\/span>","<span class=\"advgb-post-tax-term\">Novartis AG<\/span>","<span class=\"advgb-post-tax-term\">PAH<\/span>","<span class=\"advgb-post-tax-term\">Pfizer Inc and Eli Lilly &amp; Co<\/span>","<span class=\"advgb-post-tax-term\">Pulmonary arterial hypertension<\/span>","<span class=\"advgb-post-tax-term\">Tracleer (bosentan)<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 11 years ago","modified":"Updated 1 year ago"},"absolute_dates":{"created":"Posted on Jun 3, 2015","modified":"Updated on May 5, 2025"},"absolute_dates_time":{"created":"Posted on Jun 3, 2015 4:42 pm","modified":"Updated on May 5, 2025 5:35 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/574","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=574"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/574\/revisions"}],"predecessor-version":[{"id":31673,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/574\/revisions\/31673"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=574"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=574"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=574"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=574"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=574"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}